BIOGEN INC (IDP.DE) Fundamental Analysis & Valuation

FRA:IDP • US09062X1037

Current stock price

156.88 EUR
-0.08 (-0.05%)
Last:

This IDP.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. IDP.DE Profitability Analysis

1.1 Basic Checks

  • In the past year IDP was profitable.
  • IDP had a positive operating cash flow in the past year.
  • Each year in the past 5 years IDP has been profitable.
  • Each year in the past 5 years IDP had a positive operating cash flow.
IDP.DE Yearly Net Income VS EBIT VS OCF VS FCFIDP.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • IDP's Return On Assets of 4.39% is fine compared to the rest of the industry. IDP outperforms 79.17% of its industry peers.
  • IDP has a Return On Equity of 7.08%. This is amongst the best in the industry. IDP outperforms 80.56% of its industry peers.
  • IDP has a better Return On Invested Capital (8.93%) than 80.56% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for IDP is below the industry average of 11.59%.
  • The 3 year average ROIC (8.93%) for IDP is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
IDP.DE Yearly ROA, ROE, ROICIDP.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 13.07%, IDP is in the better half of the industry, outperforming 79.17% of the companies in the same industry.
  • IDP's Profit Margin has declined in the last couple of years.
  • IDP's Operating Margin of 27.94% is amongst the best of the industry. IDP outperforms 81.94% of its industry peers.
  • In the last couple of years the Operating Margin of IDP has declined.
  • IDP's Gross Margin of 75.69% is fine compared to the rest of the industry. IDP outperforms 70.83% of its industry peers.
  • IDP's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
IDP.DE Yearly Profit, Operating, Gross MarginsIDP.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. IDP.DE Health Analysis

2.1 Basic Checks

  • IDP has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, IDP has more shares outstanding
  • Compared to 5 years ago, IDP has less shares outstanding
  • Compared to 1 year ago, IDP has an improved debt to assets ratio.
IDP.DE Yearly Shares OutstandingIDP.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
IDP.DE Yearly Total Debt VS Total AssetsIDP.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • IDP has an Altman-Z score of 3.30. This indicates that IDP is financially healthy and has little risk of bankruptcy at the moment.
  • With a Altman-Z score value of 3.30, IDP perfoms like the industry average, outperforming 59.72% of the companies in the same industry.
  • The Debt to FCF ratio of IDP is 3.11, which is a good value as it means it would take IDP, 3.11 years of fcf income to pay off all of its debts.
  • IDP has a Debt to FCF ratio of 3.11. This is amongst the best in the industry. IDP outperforms 84.72% of its industry peers.
  • IDP has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.34, IDP is in line with its industry, outperforming 58.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.3
ROIC/WACC0.98
WACC9.15%
IDP.DE Yearly LT Debt VS Equity VS FCFIDP.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that IDP has no problem at all paying its short term obligations.
  • IDP has a Current ratio (2.68) which is in line with its industry peers.
  • IDP has a Quick Ratio of 2.03. This indicates that IDP is financially healthy and has no problem in meeting its short term obligations.
  • IDP has a Quick ratio of 2.03. This is comparable to the rest of the industry: IDP outperforms 52.78% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
IDP.DE Yearly Current Assets VS Current LiabilitesIDP.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. IDP.DE Growth Analysis

3.1 Past

  • IDP shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.16%.
  • The earnings per share for IDP have been decreasing by -14.17% on average. This is quite bad
  • IDP shows a small growth in Revenue. In the last year, the Revenue has grown by 2.22%.
  • Measured over the past years, IDP shows a decrease in Revenue. The Revenue has been decreasing by -5.96% on average per year.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • IDP is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.27% yearly.
  • The Revenue is expected to grow by 0.45% on average over the next years.
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y4.27%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y0.45%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IDP.DE Yearly Revenue VS EstimatesIDP.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
IDP.DE Yearly EPS VS EstimatesIDP.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. IDP.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 12.01, IDP is valued correctly.
  • 90.28% of the companies in the same industry are more expensive than IDP, based on the Price/Earnings ratio.
  • IDP is valuated cheaply when we compare the Price/Earnings ratio to 26.54, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 11.39, which indicates a very decent valuation of IDP.
  • Based on the Price/Forward Earnings ratio, IDP is valued cheaper than 97.22% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 21.68. IDP is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 12.01
Fwd PE 11.39
IDP.DE Price Earnings VS Forward Price EarningsIDP.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, IDP is valued cheaper than 88.89% of the companies in the same industry.
  • IDP's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IDP is cheaper than 97.22% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.35
EV/EBITDA 8.08
IDP.DE Per share dataIDP.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • IDP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.21
PEG (5Y)N/A
EPS Next 2Y3.4%
EPS Next 3Y3.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDP.DE Dividend Analysis

5.1 Amount

  • IDP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDP.DE Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

FRA:IDP (4/29/2026, 7:00:00 PM)

156.88

-0.08 (-0.05%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength54.66
Industry Growth13.04
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners98.03%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap23.02B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target183.33 (16.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)3.56%
PT rev (3m)12.35%
EPS NQ rev (1m)-2.32%
EPS NQ rev (3m)-15.21%
EPS NY rev (1m)0.27%
EPS NY rev (3m)4.37%
Revenue NQ rev (1m)0.61%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)0.42%
Revenue NY rev (3m)1.6%
Valuation
Industry RankSector Rank
PE 12.01
Fwd PE 11.39
P/S 2.72
P/FCF 13.35
P/OCF 12.23
P/B 1.48
P/tB 10.42
EV/EBITDA 8.08
EPS(TTM)13.06
EY8.32%
EPS(NY)13.77
Fwd EY8.78%
FCF(TTM)11.75
FCFY7.49%
OCF(TTM)12.83
OCFY8.18%
SpS57.57
BVpS106.27
TBVpS15.06
PEG (NY)2.21
PEG (5Y)N/A
Graham Number176.712 (12.64%)
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.3
F-Score4
WACC9.15%
ROIC/WACC0.98
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.45%
EPS Next 2Y3.4%
EPS Next 3Y3.98%
EPS Next 5Y4.27%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.54%
Revenue Next 2Y-1.96%
Revenue Next 3Y-0.91%
Revenue Next 5Y0.45%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year17.07%
EBIT Next 3Y5.07%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / IDP.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIOGEN INC (IDP.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to IDP.DE.


What is the valuation status for IDP stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (IDP.DE). This can be considered as Undervalued.


How profitable is BIOGEN INC (IDP.DE) stock?

BIOGEN INC (IDP.DE) has a profitability rating of 7 / 10.


Can you provide the PE and PB ratios for IDP stock?

The Price/Earnings (PE) ratio for BIOGEN INC (IDP.DE) is 12.01 and the Price/Book (PB) ratio is 1.48.


What is the earnings growth outlook for BIOGEN INC?

The Earnings per Share (EPS) of BIOGEN INC (IDP.DE) is expected to grow by 5.45% in the next year.